Biopharma

Busy biopharma M&A activity closed out 2018

During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in […]

Biopharma licensing finished with a strong Q4

During the fourth quarter of 2018, Cortellis Competitive Intelligence   registered 1,073 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $46.1 billion as part of its ongoing coverage of licensing activity in the life sciences sector. The totals represented a 7.4% increase from 994 and a 41.4% increase from $27 billion […]

Biopharma M&A engine fires up as new year rings in big deals

Bristol-Myers Squibb (BMS) Co.’s $74 billion bid for Celgene Corp. – which, if it closes, will become the largest M&A in biopharma history – “made for a fascinating opening” to the J.P. Morgan Healthcare Conference (JPM), said Jamie Munro, global practice leader, portfolio and licensing at Clarivate Analytics, especially given Celgene’s historic placemark as the […]

Key Q2 partnerships driving biopharma

Introduction During the second quarter of 2018, Cortellis Competitive Intelligence registered 985 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $19.5 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 964 and $35.6 billion in the first quarter and 1,104 and $13.6 […]

European biotech on course for record year with $3.9B raised in first half of 2018

This is the second of a two-part series on Life Sciences Connect looking at the current robust financial climate for biopharma. “Biopharma IPOs gone wild,” also via BioWorld, the daily biopharma news service from Clarivate Analytics, appeared on July 10, 2018. European biotechnology firms engaged in drug development raised $3,904 million during the first half […]

Biopharma IPOs gone wild: Highest amount ever raised as 14 companies join public ranks

This is the first of a two-part series on “Life Sciences Connect” looking at the current robust financial climate for biopharma. Watch for a report, also via BioWorld, the daily biopharma news service from Clarivate Analytics, on the record pace of fund raising in Europe shortly. The public offerings by immuno-oncology-focused Forty Seven Inc., which […]

Life sciences M&A deals in the fourth quarter of 2017: updates and trends

During the fourth quarter of 2017, Cortellis Deals Intelligence registered 122 new mergers and acquisitions (M&A) with a total disclosed deal value of $92.3 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 121 and $30.1 billion in the third quarter and 111 and $22 billion in […]

FDA guidance recommends diversity in clinical trials for medical devices, but can’t require it

The FDA often stresses the importance of enrolling diverse patient populations in clinical trials conducted to support product applications — both in industry guidance documents and during interactions with product sponsors. In Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies, guidance released in September 2017, the FDA makes multiple […]

Life sciences licensing deals in the fourth quarter of 2017: updates and trends

During the fourth quarter of 2017, Cortellis Competitive Intelligence registered 1,107 new deals (excluding mergers & acquisitions) as part of its ongoing coverage of licensing activity in the life sciences sector compared to 1,043 in the third quarter and 1,035 in the fourth quarter of 2016.   High-value deals: worth $0.5 billion or more We […]